Evidence map›Paper›PMID 26010511›Full record

ArticlePloS one2015

Identification of Non-HIV Immunogens That Bind to Germline b12 Predecessors and Prime for Elicitation of Cross-clade Neutralizing HIV-1 Antibodies.

Zheng Yang, Jingjing Li, Qingsheng Liu, Tingting Yuan, Yanyu Zhang, Li-Qing Chen, Qi Lou, Zehua Sun, Huazhong Ying, Jianqing Xu and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Zheng YangAIDS Institute, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong, China.
Jingjing LiAIDS Institute, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong, China.
Qingsheng LiuAIDS Institute, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong, China.
Tingting YuanAIDS Institute, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong, China.
Yanyu ZhangAIDS Institute, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong, China.
Li-Qing ChenCenter of Laboratory Animals, Zhejiang Academy of Medical Sciences, Zhejiang, China.
Qi LouCenter of Laboratory Animals, Zhejiang Academy of Medical Sciences, Zhejiang, China.
Zehua SunAIDS Institute, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong, China.
Huazhong YingCenter of Laboratory Animals, Zhejiang Academy of Medical Sciences, Zhejiang, China.
Jianqing XuInstitutes of Biomedical Sciences, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China.
Dimiter S DimitrovProtein Interactions group, Laboratory of Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland, United States of America.
Mei-Yun ZhangAIDS Institute, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong, China; Liver Disease Institute, Shenzhen Third People's Hospital, Shenzhen, 518112, China.
University of Hong Kong · HKZhejiang Academy of Medical Sciences · CNNational Institutes of Health · USShanghai Public Health Clinical Center · CNShenzhen Third People’s Hospital · CN

Funding

Antibody-based therapeutics and vaccines against AIDSZIABC011155 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI DIMITROV, DIMITER S · 2009 to 2017
$2.6M
6 · The paper itself

Abstract

A fundamental challenge for developing an effective and safe HIV-1 vaccine is to identify vaccine immunogens that can initiate and maintain immune responses leading to elicitation of broadly neutralizing HIV-1 antibodies (bnAbs) through complex maturation pathways. We have previously found that HIV-1 envelope glycoproteins (Env) lack measurable binding to putative germline predecessors of known bnAbs and proposed to search for non-HIV immunogens that could initiate their somatic maturation. Using bnAb b12 as a model bnAb and yeast display technology, we isolated five (poly)peptides from plant leaves, insects, E. coli strains, and sea water microbes that bind to b12 putative germline and intermediate antibodies. Rabbit immunization with the (poly)peptides alone induced high titers of cross-reactive antibodies that neutralized HIV-1 isolates SF162 and JRFL. Priming rabbits with the (poly)peptides followed by boosts with trimeric gp140SF162 and then resurfaced Env (RSC3) induced antibodies that competed with mature b12 and neutralized tier 1 and 2 viruses from clade B, C and E, while control rabbits without (poly)peptide priming induced antibodies that did not compete with mature b12 and neutralized fewer isolates. The degree of competition with mature b12 for binding to gp140SF162 correlated with the neutralizing activity of the rabbit IgG. Reversing the order of the two boosting immunogens significantly affected the binding profile and neutralization potency of the rabbit IgG. Our study is the first to provide evidence that appears to support the concept that non-HIV immunogens may initiate immune responses leading to elicitation of cross-clade neutralizing antibodies.

Indexed as

Amino Acid SequenceAnimalsAntibodies, NeutralizingConsensus SequenceCross-PrimingCross ReactionsEnzyme-Linked Immunosorbent AssayFemaleGerm CellsHIV-1HIV AntibodiesHIV InfectionsHumansImmunizationImmunoglobulin GMacacaAntibodies, NeutralizingHIV AntibodiesImmunoglobulin GPeptides

Identifiers

PMID26010511
PMCPMC4444298
OpenAlexW1489681541

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.